TVT2017: 4C MR therapy could be safer than other TMVR approaches

A new mitral regurgitation (MR) therapy designed to treat patients with structural heart disease was shown to be a safer treatment option than other transcatheter mitral valve replacement (TMVR) in a presentation at this year’s Transcatheter Valve Therapies (TVT) conference in Chicago.

The valve, designed by 4C Medical Technologies in Brooklyn Park, Minnesota, is the first MR therapy that preserves the native mitral valve and left ventricle using a supra-annular, atrial-only fixation technology.

Its design also eliminates issues with some TMVR technologies that rely on placement and fixation in the native mitral annulus and left ventricle. Challenges associated with current TMVR approaches are related to the complexity of the mitral valve anatomy and the multitude of MR mechanisms.

"4C Medical's mitral valve is an innovative and simple solution for a very common problem, and its unique mechanism will allow treatment of many patients not suitable for current TMVR devices," said Philippe Généreux, MD, the co-director of the structural heart program and the Gagnon Cardiovascular Institute of Morristown Medical Center in New Jersey, in a statement. "30-day pre-clinical results are promising and demonstrate concept feasibility and safety, with no hemodynamic compromise, no thrombus, and mild-to-no MR as confirmed by echocardiography."

4C’s device preserves the native vale apparatus position in the left atrium, which helps avoids issues related to the complexity and dynamism of the mitral annulus.

"We are dedicated to innovating therapies for structural heart disease through clinical research in partnership with Key Opinion Leaders," said Robert Thatcher, CEO of 4C Medical Technologies, in a statement. "More than half of symptomatic MR patients are not candidates for surgery, and we are driven to develop new solutions that clinicians can use to improve the quality of life for these patients."

 

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."